PharmacyCodes



Metilfenidato [Inn-Spanish] en es it fr

Metilfenidato [Inn-Spanish] Brand names, Metilfenidato [Inn-Spanish] Analogs

Metilfenidato [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Metilfenidato [Inn-Spanish] Chemical_Formula

C14H19NO2

Metilfenidato [Inn-Spanish] RX_link

http://www.rxlist.com/cgi/generic/methphen.htm

Metilfenidato [Inn-Spanish] fda sheet

Metilfenidato_[Inn-Spanish] FDA

Metilfenidato [Inn-Spanish] msds (material safety sheet)

Metilfenidato_[Inn-Spanish] MSDS

Metilfenidato [Inn-Spanish] Synthesis Reference

M. Hartmann, L. Panizzon, U.S. Pat. 2,507,631 (1950)

Metilfenidato [Inn-Spanish] Molecular Weight

233.306 g/mol

Metilfenidato [Inn-Spanish] Melting Point

224-226oC

Metilfenidato [Inn-Spanish] H2O Solubility

1255mg/L

Metilfenidato [Inn-Spanish] State

Solid

Metilfenidato [Inn-Spanish] LogP

3.192

Metilfenidato [Inn-Spanish] Dosage Forms

Tablets; Tablets (sustained release)

Metilfenidato [Inn-Spanish] Indication

For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Metilfenidato [Inn-Spanish] Pharmacology

Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

Metilfenidato [Inn-Spanish] Absorption

Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)

Metilfenidato [Inn-Spanish] side effects and Toxicity

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)

Metilfenidato [Inn-Spanish] Patient Information

Metilfenidato [Inn-Spanish] Organisms Affected

Humans and other mammals